Access cutting-edge hiv prevention treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access hiv prevention specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hiv prevention treatment provided free
HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing monoclonal antibodies given intravenously in adult participants without HIV. The hypothesis of the study is that the combination of VRC07-523LS and PGT121.414.LS and PGDM1400LS antibodies when administered via the intravenous (IV) route will be safe and tolerable in adult
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Check if you qualify for this hiv prevention clinical trial in New York, NY
If you're searching for hiv prevention treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hiv prevention specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.